Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment

Apathy, depression, and anxiety are among the most important non-motor signs of Parkinson’s disease (PD). This may be encountered at early stages of illness and represent a major source of burden. Understanding their pathophysiology is a major prerequisite for efficient therapeutic strategies. Anatomical and metabolic imaging studies have enabled a breakthrough by demonstrating that widespread abnormalities within the limbic circuits notably the orbitofrontal and anterior cingulate cortices, amygdala, thalamus, and ventral striatum are involved in the pathophysiology of depression, anxiety, and apathy in PD. Functional imaging has further shown that mesolimbic dopaminergic but also serotonergic lesions play a major role in the mechanisms of these three neuropsychiatric manifestations, which has direct therapeutic implications.

[1]  N. Bohnen,et al.  Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  A. Björklund,et al.  Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson’s Patients Treated with Dopamine Grafts , 2012, Science Translational Medicine.

[3]  Min Xuan,et al.  Altered brain network centrality in depressed Parkinson's disease patients , 2015, Movement disorders : official journal of the Movement Disorder Society.

[4]  T R Ten Have,et al.  Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease , 2010, Neurology.

[5]  J. Velíšková,et al.  Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study , 2003, European journal of neurology.

[6]  Yonggui Yuan,et al.  Altered Resting-State Brain Activity and Connectivity in Depressed Parkinson’s Disease , 2015, PloS one.

[7]  J. Régis,et al.  A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation , 2015, Movement disorders : official journal of the Movement Disorder Society.

[8]  R. Marconi,et al.  Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease , 2006, Journal of Neurology.

[9]  Xiaoqi Huang,et al.  Resting-state fMRI study on drug-naive patients with Parkinson's disease and with depression , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  L. Tremblay,et al.  Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states , 2018, Journal of Neural Transmission.

[11]  R. Hauser,et al.  Sertraline for the treatment of depression in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[12]  A. Lozano,et al.  Deep Brain Stimulation for Treatment-Resistant Depression , 2005, Neuron.

[13]  Weidong Fang,et al.  Altered Spontaneous Brain Activity in Patients with Parkinson’s Disease Accompanied by Depressive Symptoms, as Revealed by Regional Homogeneity and Functional Connectivity in the Prefrontal-Limbic System , 2014, PloS one.

[14]  A. Lawrence,et al.  Apathy blunts neural response to money in Parkinson's disease , 2011, Social neuroscience.

[15]  Nora Turjanski,et al.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. , 2005, Brain : a journal of neurology.

[16]  D. Brooks,et al.  Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures , 2010, Neurology.

[17]  Alan A. Wilson,et al.  Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease , 2007, European journal of neurology.

[18]  Wim E J Weber,et al.  Neuroanatomical correlates of apathy in Parkinson's disease: A magnetic resonance imaging study using voxel‐based morphometry , 2010, Movement disorders : official journal of the Movement Disorder Society.

[19]  P. Pollak,et al.  The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease , 1999, Journal of the Neurological Sciences.

[20]  E. Tolosa,et al.  Resting‐state frontostriatal functional connectivity in Parkinson's disease–related apathy , 2015, Movement disorders : official journal of the Movement Disorder Society.

[21]  R. Camicioli,et al.  Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms. , 2012, Parkinsonism & related disorders.

[22]  C. Mariani,et al.  Tolerability of paroxetine in Parkinson's disease: A prospective study , 2000, Movement disorders : official journal of the Movement Disorder Society.

[23]  Irena Rektorova,et al.  Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[24]  L. Tremblay,et al.  Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[25]  Y. Liu,et al.  Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease , 2013, NeuroImage.

[26]  M. T. Pellecchia,et al.  Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. , 2015, Parkinsonism & related disorders.

[27]  L. Murri,et al.  Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms , 2000, Neurology.

[28]  J. J. Lee,et al.  Apathy and striatal dopamine defects in non-demented patients with Parkinson's disease. , 2016, Parkinsonism & related disorders.

[29]  Y. Agid,et al.  Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom , 2008, Movement disorders : official journal of the Movement Disorder Society.

[30]  S. Chung,et al.  Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease , 2016, Expert opinion on pharmacotherapy.

[31]  Xiaojun Xu,et al.  Cortical abnormalities in Parkinson’s disease patients and relationship to depression: A surface-based morphometry study , 2016, Psychiatry Research: Neuroimaging.

[32]  David Eidelberg,et al.  Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. , 2002, The American journal of psychiatry.

[33]  Ken-ichi Amemori,et al.  Localized Microstimulation of Primate Pregenual Cingulate Cortex Induces Negative Decision-Making , 2012, Nature Neuroscience.

[34]  L. Tremblay,et al.  Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.

[35]  Alan A. Wilson,et al.  Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB , 2008, Movement disorders : official journal of the Movement Disorder Society.

[36]  D. Aarsland,et al.  Neuropsychiatric Symptoms in Parkinson's Disease. , 2015, Journal of Parkinson's disease.

[37]  M. T. Pellecchia,et al.  Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. , 2012, Parkinsonism & related disorders.

[38]  A. Leentjens The Role of Dopamine Agonists in the Treatment of Depression in Patients with Parkinson’s Disease , 2011, Drugs.

[39]  Alan A. Wilson,et al.  Decreased binding of the D-3 dopamine receptor-preferring ligand [C-11]-()-PHNO in drug-nave Parkinsons disease , 2009 .

[40]  M. Oda,et al.  Dementia in Parkinson’s disease: diffusion tensor imaging , 2007, Acta neurologica Scandinavica.

[41]  Johannes Schwarz,et al.  Monoamine transporter availability in Parkinson’s disease patients with or without depression , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  J. Hollerman,et al.  Reward processing in primate orbitofrontal cortex and basal ganglia. , 2000, Cerebral cortex.

[43]  H. Mayberg,et al.  Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease , 1990, Annals of neurology.

[44]  N. Gasson,et al.  A Meta-Analysis of Randomised Placebo-Controlled Treatment Trials for Depression and Anxiety in Parkinson’s Disease , 2013, PloS one.

[45]  U. Bonuccelli,et al.  Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction , 2012, European journal of neurology.

[46]  Lei Zhu,et al.  The cortical thickness correlates of clinical manifestations in the mid-stage sporadic Parkinson’s disease , 2016, Neuroscience Letters.

[47]  L. Defebvre,et al.  Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[48]  L. Parsons,et al.  Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. , 1999, The American journal of psychiatry.

[49]  Alan A. Wilson,et al.  Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. , 2009, Brain : a journal of neurology.

[50]  M Filippi,et al.  Regional patterns of brain tissue loss associated with depression in Parkinson disease , 2010, Neurology.

[51]  D. Berg,et al.  Depression in Parkinson’s disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging , 1999, Journal of Neurology.

[52]  Yonggui Yuan,et al.  Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[53]  Chaorui Huang,et al.  Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [18F]Fluorodeoxyglucose Positron Emission Computed Tomography Study , 2013, Dementia and Geriatric Cognitive Disorders.

[54]  L. Defebvre,et al.  Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[55]  C. Christine,et al.  A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease , 2012, Neurology.

[56]  M. Nirenberg,et al.  Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.

[57]  R. Bressan,et al.  Higher dopamine transporter density in Parkinson’s disease patients with depression , 2010, Psychopharmacology.

[58]  H. Berendse,et al.  Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume , 2015, Movement disorders : official journal of the Movement Disorder Society.

[59]  Janneke Koerts,et al.  Striatal dopaminergic activity (FDOPA‐PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease , 2007, The European journal of neuroscience.

[60]  Q. Gong,et al.  Cortical thinning in drug-naive Parkinson’s disease patients with depression , 2016, Journal of Neurology.

[61]  M. Oda,et al.  Minor depression and brain perfusion images in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[62]  Xiaojun Xu,et al.  Abnormal amygdala function in Parkinson's disease patients and its relationship to depression. , 2015, Journal of affective disorders.

[63]  F. Skidmore,et al.  White Matter Microstructure Changes in the Thalamus in Parkinson Disease with Depression: A Diffusion Tensor MR Imaging Study , 2010, American Journal of Neuroradiology.

[64]  H. Berendse,et al.  A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer—VBM study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[65]  E. Tolosa,et al.  Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[66]  L. Yao,et al.  Abnormal Baseline Brain Activity in Non-Depressed Parkinson’s Disease and Depressed Parkinson’s Disease: A Resting-State Functional Magnetic Resonance Imaging Study , 2013, PloS one.

[67]  P. Krack,et al.  Emotional manifestations of PD: Neurobiological basis , 2016, Movement disorders : official journal of the Movement Disorder Society.

[68]  J. Péron,et al.  Apathy in patients with Parkinson disease without dementia or depression , 2012, Neurology.

[69]  J. Péron,et al.  Subthalamic nucleus stimulation in Parkinson disease induces apathy , 2009, Neurology.

[70]  L. Tremblay,et al.  The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease. , 2016, Brain : a journal of neurology.

[71]  João Ricardo Sato,et al.  Depression in Parkinson's disease: Convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus , 2009, NeuroImage.

[72]  Xiaojun Xu,et al.  Disrupted white matter integrity in depressed versus non-depressed Parkinson's disease patients: A tract-based spatial statistics study , 2014, Journal of the Neurological Sciences.

[73]  I. Katz,et al.  Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  Kenichi Komatsu,et al.  Depression in Parkinson's disease. Diffusion tensor imaging study. , 2007, Journal of neurology.

[75]  J. Seibyl,et al.  Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. , 2015, Brain : a journal of neurology.

[76]  E. Tolosa,et al.  Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non‐motor symptoms – results of a double‐blind, randomized, placebo‐controlled trial , 2015, European journal of neurology.

[77]  Paul Krack,et al.  Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. , 2013, Brain : a journal of neurology.

[78]  Liat Levita,et al.  Avoidance of harm and anxiety: A role for the nucleus accumbens , 2012, NeuroImage.

[79]  H. Reichmann,et al.  Parkinson’s disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography , 1997, Journal of neurology, neurosurgery, and psychiatry.

[80]  Mark Stacy,et al.  Clinical spectrum of impulse control disorders in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[81]  M. Hornberger,et al.  Neuropsychiatric symptoms in Parkinson's disease: fronto-striatal atrophy contributions. , 2014, Parkinsonism & related disorders.

[82]  J. Friedman,et al.  Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. , 2013, Parkinsonism & related disorders.

[83]  Z. Illés,et al.  Morphometric changes of gray matter in Parkinson's disease with depression: A voxel‐based morphometry study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[84]  C. Mariani,et al.  Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life , 2006, Movement disorders : official journal of the Movement Disorder Society.

[85]  Joong-Seok Kim,et al.  Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia , 2015, Journal of movement disorders.

[86]  L. Defebvre,et al.  Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: A magnetic resonance imaging shape analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[87]  J. Péron,et al.  Parkinson disease : A PET study Preoperative factors of apathy in subthalamic stimulated , 2022 .

[88]  R. Bressan,et al.  Increased dopamine transporter density in Parkinson's disease patients with social anxiety disorder , 2011, Journal of the Neurological Sciences.